(Reuters) – AstraZeneca said on Tuesday its study of monoclonal antibody AZD7442 did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the SARS-CoV-2 virus.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shounak Dasgupta)
